Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis.

ABSTRACT:

Introduction

Some local protocols suggest using intermediate or therapeutic doses of anticoagulants for thromboprophylaxis in hospitalized patients with coronavirus disease 2019 (COVID-19). However, the incidence of bleeding, predictors of major bleeding, or the association between bleeding and mortality remain largely unknown.

Methods

We performed a cohort study of patients hospitalized for COVID-19 that received intermediate or therapeutic doses of anticoagulants from March 25 to July 22, 2020, to identify those at increased risk for major bleeding. We used bivariate and multivariable logistic regression to explore the risk factors associated with major bleeding.

Results

During the study period, 1965 patients were enrolled. Of them, 1347 (69%) received intermediate-

SUBMITTER: Demelo-Rodriguez P 

PROVIDER: S-EPMC8237051 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature